FYERS
Wanbury227.55
+4.80 (+2.15%)

Wanbury Share Price

227.55+4.80 (+2.15%)
-9.07% past 1 Year

Corporate filings & documents

Announcements

Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.
2 weeks ago
Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.
2 weeks ago
The register of members and share transfer books of the Company will remain closed from Friday 18 September 2026 to Thursday 24 September 2026 (both days inclusive) for the purpose of Annual General Meeting.
3 weeks ago
The register of members and share transfer books of the Company will remain closed from Friday 18 September 2026 to Thursday 24 September 2026 (both days inclusive) for the purpose of Annual General Meeting.
3 weeks ago
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.
3 weeks ago
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.
3 weeks ago
Notice of the 38th Annual General Meeting to be held on Thursday September 24 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).
3 weeks ago
Notice of the 38th Annual General Meeting to be held on Thursday September 24 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).
3 weeks ago
Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday September 24 2026 at 11.30 A.M.
3 weeks ago
Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday September 24 2026 at 11.30 A.M.
3 weeks ago
Press Release regarding EDQM approval for new product Rivaroxaban API USFDA DMF Clearances.
1 month ago
Press Release regarding EDQM approval for new product Rivaroxaban API USFDA DMF Clearances.
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Press Release on Un-audited Financial Results for the quarter ended 30th June 2026
1 month ago
Press Release on Un-audited Financial Results for the quarter ended 30th June 2026
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Financial Results for the first quarter ended 30th June 2026
1 month ago
Financial Results for the first quarter ended 30th June 2026
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Outcome of the Board Meeting held on August 11 2026
1 month ago
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of Wanbury Limited isscheduled to be held on Tuesday August 11 2026 inter-alia to consider and approve the Un-audited Financial Results for the first quarter and three months ended June 30 2026.
1 month ago
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that the meeting of the Board of Directors of Wanbury Limited isscheduled to be held on Tuesday August 11 2026 inter-alia to consider and approve the Un-audited Financial Results for the first quarter and three months ended June 30 2026.
1 month ago
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs
1 month ago
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs
1 month ago
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Companys Facilty.
2 months ago
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Companys Facilty.
2 months ago
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Companys facility at Tanuku West Godavari District Andra Pradesh during the period from July 13 2026 to July 17 2026.At the Conclusion of the inspection the U.S.FDA has issued a Form 483 with six observations. The company will respond to these observations to FDA within stipulated time.
2 months ago
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Companys facility at Tanuku West Godavari District Andra Pradesh during the period from July 13 2026 to July 17 2026.At the Conclusion of the inspection the U.S.FDA has issued a Form 483 with six observations. The company will respond to these observations to FDA within stipulated time.
2 months ago
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent past under Regulation 30 of the SEBI (LODR) Regulations 2015. There is no other material event or information which needs to be informed to the stock exchanges at this point of time. The Company shall continue to disclose all relevant events or information in accordance with the timeliness prescribed under applicable laws and regulations.Therefore the increase in the price of the scrip of the Company in the recent past is completely market driven.
2 months ago
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent past under Regulation 30 of the SEBI (LODR) Regulations 2015. There is no other material event or information which needs to be informed to the stock exchanges at this point of time. The Company shall continue to disclose all relevant events or information in accordance with the timeliness prescribed under applicable laws and regulations.Therefore the increase in the price of the scrip of the Company in the recent past is completely market driven.
2 months ago
The Exchange has sought clarification from Wanbury Ltd on July 16 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
2 months ago
The Exchange has sought clarification from Wanbury Ltd on July 16 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
2 months ago
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured guaranteed senior taxable non-cumulative unrated redeemable principal protected non-convertible debentures issued by the company.
2 months ago
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured guaranteed senior taxable non-cumulative unrated redeemable principal protected non-convertible debentures issued by the company.
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Catalyst Trusteeship Ltd
2 months ago
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018.
2 months ago
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018.
2 months ago
Investor Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March 2026 and is also available on the website of the Company at www.wanbury.com
2 months ago
Investor Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March 2026 and is also available on the website of the Company at www.wanbury.com
2 months ago
Outcome of the Board Meeting - Change in Management
2 months ago
Outcome of the Board Meeting - Change in Management
2 months ago
Outcome of the Board Meeting dated 26.06.2026
2 months ago
Outcome of the Board Meeting dated 26.06.2026
2 months ago

Annual reports

FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21

Concalls & investor presentations

May 2026
ConcallPresentation
Feb 2026
ConcallPresentation

Wanbury Ltd Share Price Today

The Wanbury Ltd share price today is ₹243.55. During the trading session, the Wanbury Ltd share price opened at ₹243.10 and recorded an intraday high of ₹245.70 and a low of ₹240.00. Last closing price was ₹246.20. Over the past 52 weeks, the Wanbury Ltd share price has ranged between ₹161.50 and ₹358.85. The current Wanbury Ltd stock price reflects real-time market activity based on executed trades on the exchange.